GlassScriptPhysician profile
Stephen L Miller
NPI 1578514477
$10,852.95
in general payments reported to CMS, 2019-2025
46 companies · $1,389 in 2025
The $1,389 reported for 2025 was more than what 77% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,536 · 2020: $231 · 2021: $647 · 2022: $4,052 · 2023: $1,453 · 2024: $1,544 · 2025: $1,389.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,357 · Education: $29.03.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,357.27 |
| Education | $29.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $2,691.22 | 2019-2025 | Camzyos, Eliquis |
| Boston Scientific Corporation | $2,005.43 | 2019-2025 | Lux-Dx Insertable Cardiac Monitor, Watchman Flx, General - Therapies |
| Amgen INC. | $750.92 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $745.47 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $631.45 | 2021-2025 | Jardiance |
| Biotronik INC. | $604.78 | 2019 | |
| Pfizer INC. | $549.65 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $537.88 | 2021-2025 | Verquvo, Capvaxive, Winrevair |
| Kiniksa Pharmaceuticals International, Plc | $246.08 | 2024 | Arcalyst |
| Janssen Pharmaceuticals, INC | $222.10 | 2019-2024 | Xarelto |
| Abbott Laboratories | $189.51 | 2019-2024 | Jot Dx |
| Bayer Healthcare Pharmaceuticals INC. | $122.10 | 2023-2025 | |
| Braemar Manufacturing, LLC | $118.69 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $107.33 | 2021-2023 | Livalo, Seglentis |
| Impulse Dynamics (USA) INC. | $104.90 | 2023-2025 | Optimizer, Optimizer |
Show all 44 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.